Stephan Stilgenbauer, MD, from Ulm University, Ulm, Germany, discusses the current advancements in the treatment of chronic lymphocytic leukemia (CLL), including the development of novel agents such as venetoclax and idelalisib, CAR T-cell therapy, immunomodulatory drugs and second-generation BTK inhibitors. He explains that for further advancements to be made, research should be focused on elucidating the biology of the disease, defining subgroups of CLL and identifying more resistance markers that may guide and individualise treatment. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
